EUVIMEDEUVIMED entdecken
Crossref

Association between opioid use and treatment discontinuation in patients receiving nivolumab: a real-world database study

Kentaro Uejima, Tsutomu Takahashi, Miki Matsui, Sakae Fukushima, Nobuhiro Ooba

Supportive Care in Cancer · 2026-09 · 34 (9)

DOI: 10.1007/s00520-026-11100-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 14.08.2026. Verfasst von Kentaro Uejima und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba, 274-8555, Japan. uejima.kentarou@nihon-u.ac.jp. Hauptthemen laut MEDLINE: Nivolumab, Analgesics, Opioid, Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We evaluated the association between baseline opioid use and time to treatment discontinuation (TTD) in patients receiving nivolumab monotherapy using a nationwide real-world database. METHODS: In this retrospective cohort study using the JMDC database (enrollment: 2015-2020; follow-up through 2022), patients with non-small cell lung, gastric, colorectal, or renal cell carcinoma initiating nivolumab were classified by baseline opioid prescriptions during the 90-day pre-index period. TTD associations were evaluated using multivariable Cox proportional hazards models. Propensity score matching (PSM) and 30- and 90-day landmark analyses were performed as sensitivity analyses. RESULTS: Among 1,879 patients (763 opioid users, 1,116 non-users), baseline opioid use was associated with shorter median TTD (112 vs. 284 days; adjusted hazard ratio [aHR], 1.93; 95% CI, 1.68-2.22; P < 0.001). This association remained consistent after PSM (aHR, 1.86; 95% CI, 1.59-2.17) and in landmark analyses. No significant interaction was observed across cancer types (P for interaction = 0.452). CONCLUSION: Baseline opioid use was associated with shorter treatment persistence among patients receiving nivolumab. Baseline opioid use may serve as a pragmatic real-world marker to identify patients at increased risk of early treatment discontinuation who may benefit from closer clinical assessment and supportive care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabAnalgesics, OpioidAntineoplastic Agents, ImmunologicalNeoplasmsHumansRetrospective StudiesFemaleAgedMaleMiddle AgedDatabases, FactualTime FactorsPropensity ScoreProportional Hazards Models

Stichwörter der Autor:innen

Immune checkpoint inhibitorsNivolumabOpioidsPropensity score matchingReal-world dataTime to treatment discontinuation

Substanzen

NivolumabAnalgesics, OpioidAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba, 274-8555, Japan. uejima.kentarou@nihon-u.ac.jp.
  • School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba, 274-8555, Japan.
  • Department of Anesthesiology, Nihon University School of Medicine, Itabashi, Tokyo, Japan.
  • Department of Pharmacy, Nihon University Itabashi Hospital, Itabashi, Tokyo, Japan.

Zitieren

APA

Uejima, K., Takahashi, T., Matsui, M., Fukushima, S., & Ooba, N. (2026). Association between opioid use and treatment discontinuation in patients receiving nivolumab: a real-world database study. Supportive Care in Cancer, 34(9). https://doi.org/10.1007/s00520-026-11100-3

Vancouver

Uejima K, Takahashi T, Matsui M, Fukushima S, Ooba N. Association between opioid use and treatment discontinuation in patients receiving nivolumab: a real-world database study. Supportive Care in Cancer. 2026;34(9). doi:10.1007/s00520-026-11100-3

BibTeX
@article{Uejima2026,
  author = {Uejima, Kentaro and Takahashi, Tsutomu and Matsui, Miki and Fukushima, Sakae and Ooba, Nobuhiro},
  title = {Association between opioid use and treatment discontinuation in patients receiving nivolumab: a real-world database study},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {9},
  doi = {10.1007/s00520-026-11100-3}
}
Kostenlos starten →